1. |
Unnikrishnan R, Pradeepa R, Joshi SR, et al. Type 2 diabetes: demystifying the global epidemic. Diabetes, 2017, 66(6): 1432-1442.
|
2. |
Dixon CJ, Knight T, Binns E, et al. Clinical measures of balance in people with type two diabetes: A systematic literature review. Gait Posture, 2017, 58: 325-332.
|
3. |
Zabetian A, Sanchez IM, Narayan KM, et al. Global rural diabetes prevalence: a systematic review and meta-analysis covering 1990-2012. Diabetes Res Clin Pract, 2014, 104(2): 206-213.
|
4. |
Wu C, Qiu S, Zhu X, et al. Vitamin D supplementation and glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Metabolism, 2017, 73: 67-76.
|
5. |
Garcia-Chapa EG, Leal-Ugarte E, Peralta-Leal V, et al. Genetic epidemiology of type 2 diabetes in Mexican Mestizos. Biomed Res Int, 2017, 2017: 3937893.
|
6. |
王海鹏. 我国诊断糖尿病疾病经济负担趋势预测研究. 济南: 山东大学, 2013.
|
7. |
Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic pattern of diabetes and prediabetes in China in 2013. JAMA, 2017, 317(24): 2515-2523.
|
8. |
Marathe PH, Gao HX, Close KL. American diabetes association standards of medical care in diabetes 2017. J Diabetes, 2017, 9(4): 320.
|
9. |
American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care, 2015, 38(Suppl): S8-S16.
|
10. |
Gheibi S, Kashfi K, Ghasemi A. A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin. Biomed Pharmacother, 2017, 95: 605-613.
|
11. |
Sun W, Zhai M, Zhou Q, et al. Effects of B Vitamins overload on plasma insulin level and hydrogen peroxide generation in rats. Chin J Physiol, 2017, 60(4): 207-214.
|
12. |
Nix WA, Zirwes R, Bangert V, et al. Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy. Diabetes Res Clin Pract, 2015, 107(1): 157-165.
|
13. |
Cetin E, Civelek S, Andican G, et al. Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy. Minerva Med, 2013, 104(1): 93-101.
|
14. |
Thornalley PJ. Disturbance of thiamine metabolism in diabetes and the development and treatment of diabetic vascular complications. Clin Chem Lab Med, 2012, 50(2): A14.
|
15. |
Thornalley PJ, Babaei-Jadidi R, Al AH, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia, 2007, 50(10): 2164-2170.
|
16. |
Luong KV, Nguyen LT. The impact of thiamine treatment in the diabetes mellitus. J Clin Med Res, 2012, 4(3): 153-160.
|
17. |
Riaz S. Study of protein biomarkers of diabetes mellitus type 2 and therapy with vitamin B1. J Diabetes Res, 2015, 2015: 150176.
|
18. |
Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol, 2014, 14: 135.
|
19. |
Hozo SP, Djulbegovic BHozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 2005, 5: 13.
|
20. |
Alaei-Shahmiri F, Soares MJ, Zhao Y, et al. The impact of thiamine supplementation on blood pressure, serum lipids and C-reactive protein in individuals with hyperglycemia: a randomised, double-blind cross-over trial. Diabetes Metab Syndr, 2015, 9(4): 213-217.
|
21. |
Al-Attas O, Al-Daghri N, Alokail M, et al. Metabolic benefits of six-month thiamine supplementation in patients with and without diabetes mellitus type 2. Clin Med Insights Endocrinol Diabetes, 2014, 7: 1-6.
|
22. |
张秉涛. 维生素B1对2型糖尿病患者尿白蛋白的影响. 中国误诊学杂志, 2011, 11(15): 3577-3578.
|
23. |
Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, et al. Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naive patients with type 2 diabetes. Eur J Nutr, 2011, 50(2): 145-149.
|
24. |
Rabbani N, Alam SS, Riaz S, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia, 2009, 52(2): 208-212.
|
25. |
Alaei-Shahmiri F, Soares MJ, Zhao Y, et al. High-dose thiamine supplementation improves glucose tolerance in hyperglycemic individuals: a randomized, double-blind cross-over trial. Eur J Nutr, 2013, 52(7): 1821-1824.
|
26. |
Ge Q, Chen L, Chen K. Treatment of diabetes mellitus using iPS cells and spice polyphenols. J Diabetes Res, 2017, 2017: 5837804.
|
27. |
Alcazar-Leyva S, Alvarado-Vasquez N. Could thiamine pyrophosphate be a regulator of the nitric oxide synthesis in the endothelial cell of diabetic patients? Med Hypotheses, 2011, 76(5): 629-631.
|
28. |
Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Current diabetes reviews, 2005, 1(3): 287-298.
|
29. |
Page GL, Laight D, Cummings MH. Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease. Int J Clin Pract, 2011, 65(6): 684-690.
|
30. |
Jenco J, Krcmova LK, Solichova D, et al. Recent trends in determination of thiamine and its derivatives in clinical practice. J Chromatogr A, 2017, 1510: 1-12.
|
31. |
Adiels M, Olofsson SO, Taskinen MR, et al. Diabetic dyslipidaemia. Curr Opin Lipidol, 2006, 17(3): 238-46.
|
32. |
Karachalias N, Babaei-Jadidi R, Kupich C, et al. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci, 2005, 1043: 777-783.
|
33. |
李斌, 刘恒明. 硫胺素类药物治疗糖尿病微血管病变研究进展. 医药导报, 2007, 26(2): 177-179.
|
34. |
Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med, 1995, 155(7): 701-709.
|
35. |
Laveti D, Kumar M, Hemalatha R, et al. Anti-inflammatory treatments for chronic diseases: a review. Inflamm Allergy Drug Targets, 2013, 12(5): 349-361.
|
36. |
Pfutzner A, Schondorf T, Hanefeld M, et al. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol, 2010, 4(3): 706-716.
|
37. |
Tang Y, Fung E, Xu A, et al. C-reactive protein and ageing. Clin Exp Pharmacol Physiol, 2017, 44(Suppl 1): 9-14.
|
38. |
Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc, 2008, 83(3): 333-342.
|
39. |
Zaringhalam J, Akbari A, Zali A, et al. Long-term treatment by vitamin B1 and reduction of serum proinflammatory cytokines, hyperalgesia, and paw edema in adjuvant-induced arthritis. Basic Clin Neurosci, 2016, 7(4): 331-340.
|
40. |
Ghashut RA, McMillan DC, Kinsella J, et al. Erythrocyte concentrations of B1, B2, B6 but not plasma C and E are reliable indicators of nutrition status in the presence of systemic inflammation. Clin Nutr, 2017, 17: 54-62.
|
41. |
宋璐璐, 杨文英. 维生素B1防治糖尿病微血管并发症. 药品评价, 2009, 6(1): 26-27.
|
42. |
Nath A, Tran T, Shope TR, et al. Prevalence of clinical thiamine deficiency in individuals with medically complicated obesity. Nutr Res, 2017, 37: 29-36.
|
43. |
张培红, 杜琰. 维生素B1、B2与2型糖尿病的关系. 上海预防医学, 2013, (6): 320-321.
|
44. |
Valdes-Ramos R, Guadarrama-Lopez AL, Martinez-Carrillo BE, et al. Vitamins and type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets, 2015, 15(1): 54-63.
|